ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2013

Abstract Number: 16

Only IgG and IgA β2glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus

Anne Tebo1,2, Rohan Willis3, Troy Jaskowski1, Laurence S. Magder4, Silvia S. Pierangeli3, Ware Branch5 and Michelle Petri6, 1ARUP Laboratories, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 4Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 5Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, 6Johns Hopkins University School of Medicine, Baltimore, MD

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: systemic lupus erythematosus (SLE) and thrombosis

Session Information

Title: Antiphospholipid Syndrome: Clinical Manifestations and New Biomarkers in Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: The current APS Classification Criteria recommend testing for IgG and IgM antibodies for β2glycoprotein I (β2GPI), and do not differentiate between primary and secondary APS. This study was designed to investigate the clinical performance of different β2GPI IgG, IgM and IgA antibody tests in a SLE with arterial and/or venous thrombosis.

Methods: IgG, IgM, and IgA anti-β2GPI antibodies were determined in 200 patients from a lupus cohort with 3 ELISA (Bio-Rad, Corgenix and INOVA) and 1 fluoro-enzyme immunoassay commercial kits (Phadia), following the manufacturers’ instructions. Kits were provided at no cost by the manufacturers, and assays were performed at ARUP laboratories.  The degree of agreement between the different kits was quantified using a Kappa statistic.  Univariate and multivariate analyses were performed to assess the association between kit results and lifetime history of venous or arterial thrombosis. 

Results:

The pairwise agreement between the different kits was high for IgG and IgM with Kappa coefficients ranging from 0.64 to 0.98 and 0.74 to 0.93 respectively.  This measure was somewhat lower for IgA with Kappa coefficients ranging from 0.24 to 0.78. Twenty-seven (14%) had a history of venous thrombosis.  For all assays and all kits, those with a positive assay result were more likely to have a history of venous thrombosis than those with a negative assay result.  These differences reached statistical significance in univariate and multivariate analyses of IgG and IgA, adjusted for age, race, and anti-htn medications.  The observed differences were not statistically significant for IgM, in part due to the relatively small number of patients positive for IgM. Thirty-four patients (17 %) had a history of arterial thrombosis. There was not strong evidence of an association between the assay results and arterial thrombosis.

Table 1:  Proportion(%) with a history of Venous Thrombosis by antibody status.

Assay

Company

Proportion(%) with history of Venous Thrombosis (n=27)

P-value1

Adjusted P-value2

Antibody-positive

Antibody-negative

IgG

Phadia

6/20 (30%)

21/180 (12%)

0.04

0.015

Bio-Rad

4/9 (44%)

23/191 (12%)

0.02

0.016

Corgenix

4/10 (40%)

23/190 (12%)

0.03

0.019

INOVA

2/2 (100%)

25/198 (13%)

0.02

1.0

Any

6/22 (27%)

21/178 (12%)

0.09

0.025

IgM

Phadia

3/10 (30%)

24/190 (13%)

0.10

0.29

Bio-Rad

4/10 (40%)

23/190 (12%)

0.03

0.097

Corgenix

4/13 (31%)

23/187 (12%)

0.080

0.14

INOVA

3/8 (38%)

24/192 (13%)

0.08

0.23

Any

5/18 (28%)

22/182 (12%)

0.08

0.17

IgA

Phadia

9/36 (25%)

18/164 (11%)

0.03

0.0055

Bio-Rad

8/29 (28%)

19/171 (11%)

0.03

0.031

Corgenix

9/41 (22%)

18/159 (11%)

0.10

0.037

INOVA

7/21 (33%)

20/179 (11%)

0.01

0.0049

Any

12/56 (21%)

15/144 (10%)

0.06

0.0080

Any Assay

13/65 (20%)

14/135 (10%)

0.08

0.021

1 Fisher’s Exact Test

2.Based on Logistic Regression, controlling for age and race, and anti-htn medications.

Table 2:  Proportion (%) with a history of Arterial Thrombosis by antibody status

Assay

Company

Proportion(%) with history of Arterial Thrombosis (n=34)

P-value1

Adjusted P-value2

Antibody-positive

Antibody-negative

IgG

Phadia

2/20 (10%)

32/180 (18%)

0.50

0.40

Bio-Rad

2/9 (22%)

32/191 (17%)

0.70

0.70

Corgenix

2/10 (20%)

32/190 (17%)

0.70

0.80

INOVA

0/2 (0%)

34/198 (17%)

1.0

Too few

Any

3/22 (14%)

31/178 (17%)

1.0

0.70

IgM

Phadia

2/10 (20%)

32/190 (17%)

0.70

0.90

Bio-Rad

4/10 (40%)

30/190 (16%)

0.070

0.20

Corgenix

4/13 (31%)

30/187 (16%)

0.20

0.30

INOVA

3/8 (38%)

31/192 (16%)

0.10

0.30

Any

4/18 (22%)

30/182 (16%)

0.50

0.90

IgA

Phadia

9/36 (25%)

25/164 (15%)

0.20

0.20

Bio-Rad

4/29 (14%)

30/171 (18%)

0.80

0.40

Corgenix

6/41 (15%)

28/159 (18%)

0.80

0.50

INOVA

6/21 (29%)

28/179 (16%)

0.20

0.20

Any

10/56 (18%)

24/144 (17%)

0.84

0.80

Any Assay

12/65 (18%)

22/135 (16%)

0.70

0.80

1 Fisher’s Exact Test

2.Based on Logistic Regression, controlling for age, race, and anti-htn medications.

Conclusion:

Only IgG and IgA isotypes were associated with venous thrombosis in SLE, using the p-value adjusted for age and ethnicity. Although the IgA kits showed variable agreements, our data indicate that testing for β2 GPI IgA isotype   may be of clinical relevance in the evaluation of venous thrombosis in APS associated with SLE.


Disclosure:

A. Tebo,
None;

R. Willis,
None;

T. Jaskowski,
None;

L. S. Magder,
None;

S. S. Pierangeli,
None;

W. Branch,
None;

M. Petri,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/only-igg-and-iga-%ce%b22glycoprotein-i-antibody-isotypes-are-associated-with-venous-thrombosis-in-systemic-lupus-erythematosus/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology